Quick answer: Prior authorization automation handles step therapy for CGRP and MS drugs by automatically pulling the patient's prior tried-and-failed medications and clinical history from the EHR, mapping them against each payer's specific step-therapy policy, and assembling a complete request that documents medical necessity before submission. This closes the documentation gap that causes most first-pass denials on high-cost neurology drugs. When a denial does happen, the same system has the prior-trial record assembled and ready for appeal.
Why step therapy is the hardest part of neurology drug authorization
Step therapy is the payer rule that says a patient must try and fail cheaper drugs before the plan will cover a more expensive one. For neurology's high-cost drugs, it's the single biggest source of authorization friction.
CGRP biologics for migraine can run $6,000 to $8,000 or more per year. MS disease-modifying therapies and anti-seizure regimens carry similar price tags. Because the drugs are expensive, payers wrap them in step-therapy and prior-trial requirements that demand proof: which drugs the patient already tried, for how long, and why they failed or weren't tolerated. Miss any piece of that, and the request comes back denied.
The problem isn't that the information doesn't exist — it's that it's scattered. A patient's medication history lives across progress notes, med lists, and sometimes prior practices' records. Assembling a clean step-therapy trail by hand is slow and error-prone, which is why these auths get denied on first pass more than almost any other neurology service. The 2024 AMA prior authorization survey found 93% of physicians say PA delays patient care — and for a migraine patient waiting on a CGRP approval, that delay is felt in attacks that could have been prevented.
How does automation build the step-therapy paper trail?
Automation handles step therapy by reconstructing the patient's drug history into the exact form the payer wants. The process runs in a few steps.
- Pull the medication history. The agent reads the patient's chart — current med list, progress notes, and prescription records — to find every relevant prior drug the patient has been on.
- Identify trials and failures. It extracts what was tried, the dates, the duration, and the documented reason it was stopped (inadequate response, side effects, contraindication).
- Map to the payer's policy. It matches that history against the specific plan's step-therapy criteria for the requested drug — because a CGRP step rule under one payer isn't the same as another's.
- Flag the gaps before submission. If the policy requires two prior trials and only one is documented, the system surfaces that gap so a coordinator can fix it — rather than learning about it weeks later in a denial letter.
That last step is where the value concentrates. Catching a missing trial before submission turns a would-be denial into a first-pass approval, which is worth far more than appealing the denial after the fact.
What happens when the step-therapy request is denied anyway?
Even a well-built request sometimes gets denied, and automation's role shifts to making the appeal fast and well-documented. Because the system already assembled the prior-trial record, the appeal doesn't start from scratch.
When a denial comes back, the agent attaches the reason and routes it to a coordinator with the full clinical and step-therapy documentation already in hand. Appeals on these high-cost drugs are frequently overturned when the prior-trial history is documented properly — the original denial often reflects a documentation gap, not a genuine coverage exclusion. Having the record ready cuts the time from denial to resubmission from days of chart-digging to a quick review.
There's also a step-therapy exception path. When a patient has a documented medical reason they can't take the required first-line drug, automation can assemble the exception request — the clinical rationale for skipping a step — which is its own kind of authorization with its own documentation bar. Handling these cleanly keeps patients on the right therapy without forcing a failed trial first.
How does this connect to the rest of the revenue cycle?
Step-therapy automation doesn't live in isolation — it works best wired into eligibility and denial workflows, because the same data feeds all three.
Before the auth, an eligibility check confirms whether the drug falls under the medical or pharmacy benefit and whether step therapy even applies to that plan. After the auth, if a claim is denied, the denial workflow already has the authorization and clinical record linked, so working the denial doesn't mean re-gathering everything. The prior-trial documentation assembled for the auth is the same documentation an appeal needs.
This is where a connected platform earns its keep. Honey Health's Prior Authorization agent assembles the step-therapy record and runs alongside its eligibility and denial management agents, so a CGRP or MS-drug auth starts from a benefits check that's already run and feeds a denial workflow that already has the file. For a revenue cycle director, that connection is the difference between three disconnected queues and one chain where each step hands off clean data to the next.
What still needs a human on high-cost drug auths?
Automation assembles documentation; it doesn't make clinical or strategic calls. On step-therapy auths specifically, a few decisions stay with people.
Whether to pursue a step-therapy exception — and how to argue the clinical rationale — is a clinician's call, informed by the patient's history. Whether to appeal a contested denial on a $7,000-a-year drug, and with what argument, benefits from a revenue cycle lead who knows the payer. And peer-to-peer reviews, when a payer demands a clinician-to-clinician conversation about medical necessity, are always human.
The realistic division of labor: automation does the assembling, mapping, and flagging at volume, while your PA lead and clinicians spend their time on the exceptions and appeals where judgment actually changes the outcome. That's a better use of an experienced coordinator than copying medication lists into a portal.
What to look for in a tool that handles neurology step therapy
Not every prior authorization tool handles step therapy well — many automate submission but leave the documentation assembly to staff. A few questions separate real capability from a checkbox.
Ask whether the tool actually extracts prior-trial history from the chart, or just submits whatever a coordinator hands it. Ask how it handles payer-specific step rules, since these vary widely between plans. Ask whether it flags documentation gaps before submission or only reports denials after. And ask how it supports appeals and step-therapy exceptions, because that's where these auths are won or lost.
The regulatory direction helps here too. The CMS Interoperability and Prior Authorization Final Rule pushes major payers toward FHIR-based PA APIs with key provisions taking effect in 2027, which should make pulling and submitting clinical documentation more structured over time. Ask any vendor how they'll use those APIs to make step-therapy documentation cleaner.
Frequently asked questions
How does prior authorization automation handle step therapy?
It pulls the patient's prior tried-and-failed medications and clinical history from the EHR, maps that history against the payer's specific step-therapy policy for the requested drug, and assembles a complete request — flagging any missing trials before submission. This prevents the documentation gaps that cause most first-pass denials on high-cost neurology drugs.
Why do CGRP and MS drug prior authorizations get denied so often?
Most denials come from incomplete step-therapy documentation — the payer requires proof of prior failed drugs, and assembling that record by hand from scattered chart notes is error-prone. Automation reconstructs the full prior-trial history and flags gaps before submission, which is what drives first-pass approvals.
Can automation handle step-therapy exceptions?
Yes. When a patient has a documented medical reason they can't take a required first-line drug, automation assembles the exception request with the clinical rationale for skipping the step. The decision to pursue an exception and how to argue it stays with the clinician, but the documentation assembly is automated.
Does automation help with appeals on denied drug authorizations?
It does. Because the system already assembled the prior-trial and clinical record for the original request, an appeal starts with the documentation in hand rather than from scratch. Denials on high-cost drugs are frequently overturned when the step-therapy history is documented properly, so fast, well-documented appeals matter.
How does step-therapy automation connect to eligibility and denials?
The same patient data feeds all three. Eligibility confirms whether the drug is a medical or pharmacy benefit and whether step therapy applies; the auth assembles the prior-trial record; and if a claim is denied, the denial workflow already has the authorization and documentation linked. A connected platform passes clean data between these steps instead of re-gathering it.
Does this work for anti-seizure and other high-cost neurology drugs?
Yes. The same approach applies to any drug subject to step therapy or prior-trial requirements — anti-seizure regimens, MS disease-modifying therapies, and CGRP biologics all benefit from automated assembly of the medication history and payer-policy mapping that these authorizations require.
